Merck Sharp Dohme patents expiration
1. Belsomra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951797 | MERCK SHARP DOHME | Substituted diazepan orexin receptor antagonists |
Nov, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-253) | Jan 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2019 |
Drugs and Companies using SUVOREXANT ingredient
NCE-1 date: 13 August, 2018
Market Authorisation Date: 13 August, 2014
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
BELSOMRA family patents
2. Clarinex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7211582 | MERCK SHARP DOHME | Methods for treating urticaria using descarboethoxyloratadine |
Dec, 2014
(9 years ago) | |
| US7214684 | MERCK SHARP DOHME | Methods for the treatment of allergic rhinitis |
Dec, 2014
(9 years ago) | |
| US7214683 | MERCK SHARP DOHME | Compositions of descarboethoxyloratadine |
Dec, 2014
(9 years ago) | |
|
US7211582 (Pediatric) | MERCK SHARP DOHME | Methods for treating urticaria using descarboethoxyloratadine |
Jun, 2015
(8 years ago) | |
|
US7214683 (Pediatric) | MERCK SHARP DOHME | Compositions of descarboethoxyloratadine |
Jun, 2015
(8 years ago) | |
|
US7214684 (Pediatric) | MERCK SHARP DOHME | Methods for the treatment of allergic rhinitis |
Jun, 2015
(8 years ago) | |
| US6514520 | MERCK SHARP DOHME | Stabilized antihistamine syrup |
Jun, 2018
(5 years ago) | |
|
US6514520 (Pediatric) | MERCK SHARP DOHME | Stabilized antihistamine syrup |
Dec, 2018
(5 years ago) | |
Drugs and Companies using DESLORATADINE ingredient
Market Authorisation Date: 01 September, 2004
Treatment: Treatment of chronic idiopathic urticaria; Treatment of allergic rhinitis
Dosage: SOLUTION;ORAL
CLARINEX family patents
3. Crixivan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6645961 | MERCK SHARP DOHME | Dry granulation formulation for an HIV protease inhibitor |
Mar, 2018
(6 years ago) | |
| US6689761 | MERCK SHARP DOHME | Combination therapy for HIV infection |
Feb, 2021
(3 years ago) | |
Drugs and Companies using INDINAVIR SULFATE ingredient
Market Authorisation Date: 19 April, 2000
Treatment: Treating hiv infection with indinavir sulfate in combination with antiretroviral agents
Dosage: CAPSULE;ORAL
CRIXIVAN family patents
4. Dutrebis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820660 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 1 day ago) | |
| US7169780 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(6 months ago) | |
| US7754731 | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7435734 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
| US7217713 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
|
US7435734 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 5 days ago) | |
|
US7217713 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 5 days ago) | |
|
US7169780 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(22 days ago) | |
|
US7754731 (Pediatric) | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 06 February, 2015
Treatment: Treatment of hiv-1 infection
Dosage: TABLET;ORAL
DUTREBIS family patents
5. Januvia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 8 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | MERCK SHARP DOHME | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US6890898 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 8 months ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 2 months ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 2 months ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 16 October, 2006
Treatment: Improvement of glycemic control in adults with type 2 diabetes mellitus; Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin and/or a ppar-gamma agoni...
Dosage: TABLET;ORAL
JANUVIA family patents
6. Juvisync patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 8 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Apr, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | MERCK SHARP DOHME | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US6890898 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US8168637 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes |
Jun, 2022
(1 year, 9 months ago) | |
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 8 months ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 2 months ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 2 months ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Oct, 2026
(2 years from now) | |
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 18 September, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate; Method of treating type 2 diabetes mellitus in patients for whom treatm...
Dosage: TABLET;ORAL
JUVISYNC family patents
7. Noxafil patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5703079 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Aug, 2014
(9 years ago) | |
| US5661151 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Jul, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(7 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(7 years from now) | |
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 31, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
| New Indication(I-881) | Jun 17, 2024 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida...
Dosage: SOLUTION;INTRAVENOUS; TABLET, DELAYED RELEASE;ORAL
NOXAFIL family patents
8. Prevymis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46791 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(26 days from now) | |
| US7196086 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(26 days from now) | |
| US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(26 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| New Indication(I-916) | Jun 05, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: TABLET;ORAL; SOLUTION;INTRAVENOUS
PREVYMIS family patents
9. Rebetol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6524570 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
| US6461605 | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(7 years ago) | |
| US6177074 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
|
US6461605 (Pediatric) | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
May, 2017
(6 years ago) | |
|
US6524570 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(6 years ago) | |
|
US6177074 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(6 years ago) | |
| US6472373 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(6 years ago) | |
| US6172046 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(6 years ago) | |
|
US6472373 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(6 years ago) | |
|
US6172046 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(6 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 03 June, 1998
Treatment: Method of using rebetol capsules in combination with a conjugate comprising polyethylene glycol(peg) and an alpha interferon, including, for example, peg-intron powder for injection; Method of treatin...
Dosage: CAPSULE;ORAL
REBETOL family patents
10. Temodar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5260291 | MERCK SHARP DOHME | Tetrazine derivatives |
Aug, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5260291 (Pediatric) | MERCK SHARP DOHME | Tetrazine derivatives |
Feb, 2014
(10 years ago) | |
| US8623868 | MERCK SHARP DOHME | Processes of making and using pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(1 year, 2 months ago) | |
| US7786118 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(1 year, 2 months ago) | |
| US6987108 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same |
Sep, 2023
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Mar 15, 2012 |
Drugs and Companies using TEMOZOLOMIDE ingredient
Market Authorisation Date: 11 August, 1999
Treatment: Treatment of malignant neoplasm
Dosage: CAPSULE;ORAL; POWDER;INTRAVENOUS
TEMODAR family patents
11. Verquvo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10736896 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| US8420656 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| US9604948 | MERCK SHARP DOHME | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
Nov, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993476 | MERCK SHARP DOHME | Substituted 5-flouro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| US11439642 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| US8921377 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2026 |
Drugs and Companies using VERICIGUAT ingredient
NCE-1 date: 19 January, 2025
Market Authorisation Date: 19 January, 2021
Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...
Dosage: TABLET;ORAL
VERQUVO family patents
12. Victrelis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43298 | MERCK SHARP DOHME | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec, 2024
(7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8119602 | MERCK SHARP DOHME | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
Mar, 2027
(2 years from now) | |
| US7772178 | MERCK SHARP DOHME | Pharmaceutical formulations and methods of treatment using the same |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2016 |
| New Patient Population(NPP) | Feb 13, 2016 |
| M(M-126) | Feb 27, 2016 |
Drugs and Companies using BOCEPREVIR ingredient
NCE-1 date: 14 May, 2015
Market Authorisation Date: 13 May, 2011
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in...
Dosage: CAPSULE;ORAL
VICTRELIS family patents
13. Welireg patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(10 years from now) | |
| US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2026 |
| New Indication(I-931) | Dec 14, 2026 |
| Orphan Drug Exclusivity(ODE-364) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 13 August, 2025
Market Authorisation Date: 13 August, 2021
Treatment: Treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand inhibitor and a vascular endothelial growth factor tyrosine kinase inh...
Dosage: TABLET;ORAL
WELIREG family patents